SenzaGen

SenzaGen Treasury Stock

The Treasury Stock of SenzaGen (SENZA.ST) as of Nov 17, 2026 is 294.90 M SEK. In the previous year, Treasury Stock was 35.81 M SEK — a change of 723.64% (higher).

Treasury Stock

294.90 MSEK

YoY

723.64%

Last updated:

Treasury Stock of SenzaGen is 2025 294.90 M SEK. Treasury Stock of SenzaGen was 2024 35.81 M SEK. It decreases by 723.64% higher compared to the previous year.

The SenzaGen Treasury Stock history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Treasury Stock
Date
Treasury Stock
Jan 1, 2018
126.13 M SEK
Jan 1, 2019
105.71 M SEK
Jan 1, 2020
5.82 M SEK
Jan 1, 2021
2.74 M SEK
Jan 1, 2022
921,000.00 SEK
Jan 1, 2023
55,000.00 SEK
Jan 1, 2024
35.81 M SEK
Jan 1, 2025
294.90 M SEK
The SenzaGen Treasury Stock history
YEARTreasury StockYoY
294.90 MSEK+723.64%
35.81 MSEK+65,000.00%
55,000.00SEK-94.03%
921,000.00SEK-66.37%
2.74 MSEK-52.95%
5.82 MSEK-94.49%
105.71 MSEK-16.18%
126.13 MSEK+1.98%
123.68 MSEK+190.64%
42.56 MSEK+0.13%
42.50 MSEK+2,727.74%
1.50 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SenzaGen Stock analysis

What does SenzaGen do? SenzaGen AB is a Swedish biotechnology company that specializes in the development and marketing of innovative and reliable tests for assessing allergenicity. Founded in 2010 by leading experts from the academic and industry sectors, the company has become a significant player in the field of toxicology. Current methods for assessing allergenicity, such as asthma, eczema, and allergic reactions, are often inaccurate and require the use of animals, which is ethically questionable and expensive. SenzaGen AB has developed a wide range of tests based on biomolecular technologies that use human cells to assess the allergenic reactivity of chemicals and products. These tests are accurate, cost-effective, and meet the current requirements of regulatory authorities and the industry. The company is headquartered in Lund, Sweden, and currently employs about 20 people. SenzaGen AB is a leader in the development of in vitro methods for evaluating allergenicity and utilizes various platform technologies such as gene expression and proteomics analysis, as well as the use of immune cells and keratinocytes. SenzaGen AB's Microarray technology platform, based on DNA-based tests, has been recognized by the European Chemicals Agency (ECHA) as suitable for assessing allergenic reactivity. The company has also partnered with the US biotechnology company In vitro International (IVI) to distribute its allergen tests in the North American market. SenzaGen AB has developed a wide range of products that can be used in various sectors such as cosmetics, food, chemicals, and pharmaceuticals. AllergoDx™ is a test system used by the pharmaceutical and chemical industries to determine the allergenic reactivity of chemicals. GARD™ (Genomic Allergen Rapid Detection) is a rapid test used in the cosmetics and food industries to determine the allergenic reactivity of new products and avoid costly animal testing. GARDskin™ is a skin test used to determine the reactivity of substances that come into contact with the skin, primarily in the chemicals and pharmaceutical industries. Other products in the company's pipeline include GARDpotency™ and GARDair™, which are intended for assessing allergic reactions in industrial and occupational environments. SenzaGen AB has experienced significant growth in recent years and plans to expand its product range and strengthen its market position. The company's business model is based on selling tests and services to chemical, pharmaceutical, food, and cosmetic companies worldwide. Through its innovative technologies and willingness to collaborate with customers, the company has taken a leadership role in toxicology. SenzaGen AB is committed to an ethical and responsible corporate philosophy focused on sustainability and environmental protection. The company has clear goals to meet the growing demand for reliable and ethical testing methods to minimize the impact of chemicals on humans and the environment. SenzaGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SenzaGen stock

Treasury Stock of SenzaGen is 294.90 M SEK in 2025.

Treasury Stock of SenzaGen changed from 35.81 M SEK to 294.90 M SEK, representing a 723.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Treasury Stock SenzaGen since 2006 – with annual values, charts, and detailed analysis.

Treasury stock represents shares that were repurchased by the company. It reduces shareholders' equity and outstanding share count.

Treasury Stock's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Treasury Stock's SenzaGen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — SenzaGen

All Key Metrics — SenzaGen